drugset / Trial / NCT01881126

An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

NCT01881126

Phase 4 Completed 93 enrolled Allergan
RandomizedParallel-groupSingle-blindTreatment

Summary

This efficacy and safety study will evaluate LUMIGAN® RC/ LUMIGAN® .01 (bimatoprost 0.01%) alone compared to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL MALEATE-EX, 0.5%/TIMOLOL GFS 0.5% (timolol 0.5% ophthalmic gel forming solution) in patients who require IOP lowering therapy.

Timeline

Start
2013-06
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bimatoprost Other / unclassified 0.01 % Topical
Comparator Timolol Other / unclassified 0.5 % Topical
Comparator Travoprost Other / unclassified 0.004 % Topical
Comparator Hypromellose Unknown 0.3 % Topical